GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
DK2571503T3
(en)
|
2010-05-14 |
2015-04-20 |
Dana Farber Cancer Inst Inc |
COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
|
CN105582014B
(zh)
|
2010-05-14 |
2019-06-14 |
达那-法伯癌症研究所 |
用于治疗白血病的组合物和方法
|
US9301962B2
(en)
|
2010-05-14 |
2016-04-05 |
Baylor College Of Medicine |
Male contraceptive compositions and methods of use
|
WO2012075456A1
(en)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Bromodomain inhibitors and uses thereof
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
EP2705039B1
(en)
|
2011-05-04 |
2017-07-26 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201107325D0
(en)
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
EP2721031B1
(en)
|
2011-06-17 |
2016-01-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
EP2838881B1
(en)
|
2012-04-20 |
2018-08-08 |
AbbVie Inc. |
Isoindolone derivatives
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
CN104718201A
(zh)
|
2012-06-12 |
2015-06-17 |
艾伯维公司 |
吡啶酮和哒嗪酮衍生物
|
WO2013192274A2
(en)
|
2012-06-19 |
2013-12-27 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
CN105377851B
(zh)
|
2013-03-11 |
2018-07-20 |
密执安州立大学董事会 |
Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
AU2014230816B9
(en)
|
2013-03-14 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Furopyridines as bromodomain inhibitors
|
MX369324B
(es)
|
2013-03-14 |
2019-11-05 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio.
|
EP2968360B1
(en)
|
2013-03-14 |
2021-01-20 |
ConverGene LLC |
Quinolinone derivatives for the inhibition of bromodomain-containing proteins
|
TWI719464B
(zh)
|
2013-03-15 |
2021-02-21 |
美商英塞特控股公司 |
作為bet蛋白抑制劑之三環雜環
|
AU2014256750B2
(en)
|
2013-04-26 |
2018-08-23 |
Beigene, Ltd. |
Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
WO2015004534A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
WO2015002754A2
(en)
|
2013-06-21 |
2015-01-08 |
Zenith Epigenetics Corp. |
Novel bicyclic bromodomain inhibitors
|
WO2014206150A1
(en)
*
|
2013-06-28 |
2014-12-31 |
Abbvie Inc. |
Bromodomain inhibitors
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
MX2016001037A
(es)
|
2013-07-25 |
2016-11-10 |
Dana Farber Cancer Inst Inc |
Inhibidores de factores de transcripción y usos.
|
US9855271B2
(en)
|
2013-07-31 |
2018-01-02 |
Zenith Epigenetics Ltd. |
Quinazolinones as bromodomain inhibitors
|
RS60002B1
(sr)
*
|
2013-10-18 |
2020-04-30 |
Celgene Quanticel Research Inc |
Inhibitori bromodomena
|
RU2016122654A
(ru)
|
2013-11-08 |
2017-12-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
|
RU2720237C2
(ru)
|
2013-11-18 |
2020-04-28 |
Форма Терапеутикс, Инк. |
Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
|
ES2860695T3
(es)
|
2013-11-18 |
2021-10-05 |
Forma Therapeutics Inc |
Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET
|
WO2015081189A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
CN106061966B
(zh)
|
2014-01-09 |
2018-12-07 |
奥赖恩公司 |
用作溴区结构域抑制剂的双环杂环衍生物
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
WO2015117053A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
KR20160111036A
(ko)
|
2014-01-31 |
2016-09-23 |
다나-파버 캔서 인스티튜트 인크. |
디아제판 유도체 및 그의 용도
|
AU2015222887B2
(en)
|
2014-02-28 |
2019-06-27 |
The Regents Of The University Of Michigan |
9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
|
CN106456653A
(zh)
|
2014-02-28 |
2017-02-22 |
腾沙治疗公司 |
高胰岛素血症相关病症的治疗
|
DK3674302T3
(da)
|
2014-04-23 |
2023-04-03 |
Incyte Holdings Corp |
1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
|
US9969747B2
(en)
|
2014-06-20 |
2018-05-15 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
|
CN106715437A
(zh)
|
2014-08-08 |
2017-05-24 |
达纳-法伯癌症研究所股份有限公司 |
二氮杂环庚烷衍生物及其用途
|
EP3177147A4
(en)
|
2014-08-08 |
2018-01-24 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
PT3191476T
(pt)
|
2014-09-12 |
2019-01-17 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de tetra-hidroquinolina como inibidores de bromodomínio
|
US9527864B2
(en)
|
2014-09-15 |
2016-12-27 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
KR20170068597A
(ko)
|
2014-10-27 |
2017-06-19 |
텐샤 세러퓨틱스 인코포레이티드 |
브로모도메인 저해제
|
EP3227281A4
(en)
|
2014-12-01 |
2018-05-30 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
JP2017537946A
(ja)
|
2014-12-11 |
2017-12-21 |
ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. |
ブロモドメイン阻害剤としての置換複素環
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
WO2016138332A1
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of Michigan |
9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
EP3314005A1
(en)
|
2015-06-26 |
2018-05-02 |
Tensha Therapeutics, Inc. |
Treatment of nut midline carcinoma
|
WO2017027571A1
(en)
|
2015-08-10 |
2017-02-16 |
Dana-Farber Cancer Institute, Inc. |
Mechanism of resistance to bet bromodomain inhibitors
|
EA033679B1
(ru)
|
2015-09-02 |
2019-11-15 |
Glaxosmithkline Ip No 2 Ltd |
Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
|
SG10202007099TA
(en)
|
2015-09-11 |
2020-08-28 |
Dana Farber Cancer Inst Inc |
Acetamide thienotriazoldiazepines and uses thereof
|
AU2016319116B2
(en)
|
2015-09-11 |
2020-10-01 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
CN108137541B
(zh)
|
2015-09-22 |
2021-07-06 |
葛兰素史克知识产权第二有限公司 |
用于用作溴结构域抑制剂的吡啶酮二甲酰胺
|
US10471050B2
(en)
|
2015-10-05 |
2019-11-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
KR20180081809A
(ko)
|
2015-11-25 |
2018-07-17 |
다나-파버 캔서 인스티튜트 인크. |
2가 브로모도메인 억제제 및 그의 용도
|
ES2882066T3
(es)
|
2016-02-15 |
2021-12-01 |
Univ Michigan Regents |
1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
|
CN113788818A
(zh)
|
2016-04-06 |
2021-12-14 |
密执安大学评议会 |
Mdm2蛋白质降解剂
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
US10934272B2
(en)
|
2016-04-07 |
2021-03-02 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
BR112018070514A2
(pt)
|
2016-04-07 |
2019-01-29 |
Glaxosmithkline Ip No 2 Ltd |
composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
|
MX2018012379A
(es)
|
2016-04-12 |
2019-07-04 |
Univ Michigan Regents |
Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
|
TWI764237B
(zh)
|
2016-04-15 |
2022-05-11 |
美商艾伯維有限公司 |
溴域抑制劑
|
EP3464242A1
(en)
|
2016-05-24 |
2019-04-10 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
KR102643344B1
(ko)
|
2016-06-20 |
2024-03-07 |
인사이트 코포레이션 |
Bet 저해제의 결정질 고체 형태
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
US10975093B2
(en)
|
2016-09-13 |
2021-04-13 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET protein degraders
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
JP7129973B2
(ja)
*
|
2016-10-20 |
2022-09-02 |
セルジーン クオンティセル リサーチ,インク. |
ブロモドメイン阻害剤
|
US11028051B2
(en)
|
2016-12-13 |
2021-06-08 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
EP3577120A1
(en)
|
2017-02-03 |
2019-12-11 |
The Regents of The University of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
WO2019055444A1
(en)
|
2017-09-13 |
2019-03-21 |
The Regents Of The University Of Michigan |
DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥(上海)股份有限公司 |
治療前列腺癌之組合療法
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023205251A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
Compounds active towards bromodomains
|